Developing game changing treatments and cell therapies for severe diseases
Important message to ALS patients and healthcare professionals, who have enquiries about our drug candidate ILB®
The articles published in the journal “Neurologi i Sverige” in February 2025 have raised significant interest from patients, their relatives and neurologists treating ALS patients.
TikoMed wants to clarify that no clinical trial in ALS is currently available for patient participation.
TikoMed is in a process of planning the next stage of development which will include clinical trials allowing for patients to participate and benefit from ILB® treatment.
No ILB® treatment is available outside of a clinical trial setting.
We recommend you follow our clinical trial progress at The EU Clinical Trials Register at www.clinicaltrialsregister.eu or via our website www.tikomed.com.
If you are considering joining a clinical trial, please contact your healthcare professional for advice and direction.
We sincerely appreciate your interest.
The articles published in the journal “Neurologi i Sverige” in February 2025 have raised significant interest from patients, their relatives and neurologists treating ALS patients.
TikoMed wants to clarify that no clinical trial in ALS is currently available for patient participation.
TikoMed is in a process of planning the next stage of development which will include clinical trials allowing for patients to participate and benefit from ILB® treatment.
No ILB® treatment is available outside of a clinical trial setting.
We recommend you follow our clinical trial progress at The EU Clinical Trials Register at www.clinicaltrialsregister.eu or via our website www.tikomed.com.
If you are considering joining a clinical trial, please contact your healthcare professional for advice and direction.
We sincerely appreciate your interest.
We develop and commercialize innovative treatments for patients with severe and life-threatening conditions. Our drug candidates have the potential to improve outcomes in the treatment of neurological and ophthalmic disease and for ground-breaking regenerative cell therapies. They give hope for patients lacking satisfactory alternatives.
News
ALS-medicinen ger Erik framtidshopp
ILB is the ALS treatment that gives Erik from Sweden hope. Read the article in “Neurologi i Sverige”.
Möjligt paradigmskifte vid ALS-behandling
Read the latest news from «Neurologi i Sverige” about ILB from TikoMed. Professor Ann Logan, Scientific Director, Neuregenix Ltd, describes ILB to be a game changing treatment for many devastating
TikoMed announces the publication of results from an open-label, single arm, single center phase II trial carried out at the Queen Elizabeth Hospital, Birmingham, UK, by the University of Birmingham’s Drugs, Devices, Diagnostics and Biomarkers (D3B) team in patients with confirmed Amyotrophic Lateral Sclerosis (ALS) treated with weekly ILB® injections.
The trial outcomes demonstrated that: TikoMed is now moving forward with planning a phase IIb multi-centre efficacy trial of ILB® Viken, Sweden July 22nd, 2024: Swedish drug development company TikoMed